Agenus

Agenus Forward P/E

The Forward P/E Ratio of Agenus (AGEN) as of Oct 16, 2026 is 863.52. In the previous year, Forward P/E Ratio was -0.44 — a change of -197,675.65% (higher).

Forward P/E

863.52

YoY

-197,675.65%

Last updated:

Forward P/E Ratio of Agenus is 2025 863.52 . Forward P/E Ratio of Agenus was 2024 -0.44 . It decreases by -197,675.65% higher compared to the previous year.

The Agenus Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
-0.62 USD
Jan 1, 2019
-0.92 USD
Jan 1, 2020
-0.55 USD
Jan 1, 2021
-4.15 USD
Jan 1, 2022
-0.45 USD
Jan 1, 2023
-0.40 USD
Jan 1, 2024
-0.44 USD
Jan 1, 2025
863.52 USD
The Agenus Forward P/E history
YEARForward P/EYoY
863.52-197,675.65%
-0.44+8.16%
-0.40-10.45%
-0.45-89.13%
-4.15+656.14%
-0.55-40.49%
-0.92+48.33%
-0.62-24.42%
-0.82+5.22%
-0.78-30.80%
-1.13-51.66%
-2.34—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Agenus Stock analysis

What does Agenus do? Agenus Inc, listed under the ticker AGEN, is a biotechnology company based in Lexington, United States. The company operates within the Health Care sector, specifically in the Biotechnology industry. Agenus Inc has a workforce of 81 employees. It went public through an IPO on February 4, 2000. The company's website is http://agenusbio.com/. Agenus Inc is engaged in the development of technologies aimed at treating cancers and infectious diseases. The company focuses on therapies that harness the immune system to combat cancer. Agenus Inc's activities include the development of antibody discovery platforms, such as Retrocyte Display, SECANT yeast display, and phage display technologies, which are used to create human antibodies. Additionally, the company is involved in the development of vaccine programs, including Prophage, AutoSynVax, and PhosPhoSynVax, as well as saponin-based vaccine adjuvants, notably QS-21 Stimulon. The company's discovery pipeline features checkpoint modulating (CPM) antibodies. Agenus Inc also works with heat shock protein (HSP)-based Prophage vaccine candidates and synthetic vaccine candidates, such as ASV and PSV. The company's headquarters are located in Lexington, Massachusetts, and it maintains a focus on advancing immuno-oncology research and development. Agenus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Agenus stock

Forward P/E Ratio of Agenus is 863.52 in 2025.

Forward P/E Ratio of Agenus changed from -0.44 to 863.52, representing a -197,675.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Agenus since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Agenus with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Agenus

All Key Metrics — Agenus